“…With an effect on neurotransmitter modulation (Goggi et al., 2002; Guillin et al., 2001; Swanwick et al., 2006; Thoenen, 1995), BDNF is implicated in the pertinent neuroadaptation of AWS, and thus mediates various clinical exhibitions such as DTs. DTs, a severe form of AWS, has even been considered as an independent clinical entity (Hemmingsen and Kramp, 1988). The reason an individual develops DTs is still unknown.…”